Cased Based Approaches to Treatment of Pregnancy and Anthracycline Cardiomyopathy
|
|
- Gregory Bryant
- 5 years ago
- Views:
Transcription
1 Cased Based Approaches to Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER MEDICAL DIRECTOR CARDIOMYOPATHY SERVICES DIRECTOR CARDIOVASCULAR GENETICS RESEARCH CO-CHAIR IRB HOUSTON, TEXAS
2 Jean-Bernard Durand, M.D. Presenter Disclosure Information I will not discuss off label use and/or investigational use in my presentation. I have the following financial relationships to disclose: Funding-NHLBI,NIH,NCI/American Cancer Society Employee of: University of Texas MD Anderson Cancer Center
3 The Initial Pre-Pregnancy Consult Higher risk of development of LVSD from Prior Anthracycline Cardiomyopathy (2.35 Fold) If concerns of pregnancy, avoid use of Ace-I, Hydralazine/Nitrates/Carvedilol Risk Management Goals for Modifiable risk factors: DM, Blood pressure, Afib and any symptoms of heart failure Fertility counseling Treated as high risk, Monthly History & Physical We have very low threshold for non-invasive Imaging
4 LVEF (EF units) Carvedilol Dose-Response Trial (MOCHA * ): Effect on Ejection Fraction and Mortality Changes in LVEF Placebo 6.25 mg bid 12.5 mg bid 25 mg bid Carvedilol Patients receiving diuretics, ACE inhibitors, ± digoxin; follow-up 6 months; placebo (n=84), carvedilol (n=261). * Multicenter Oral Carvedilol Heart Failure Assessment. Adapted from Bristow MR et al. Circulation. 1996;94: P<.05 vs placebo.
5 Blood. 118(23); Risk Of CHF Increases with CV RF and Anthracycline
6 Mean Biopsy Grade Cardiotoxicity occurs earlier than change in EF Doxorubicin was given IV every 3 to 4 weeks. Biopsy specimens were taken approximately 3 weeks following last therapy. 3 Mackay MDAH n=7 2 Billingham Stanford n=22 n=8 n=3 1 n=8 n=18 5% * 0 *Risk of CHF >500 Cumulative Doxorubicin Dose (mg/m2) Adapted from Ewer et al. J Clin Oncol 1984;2:
7 Lipshultz SE, et al Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. Oct ;128(17): Application to Onco-Cardiology Female sex and younger age at time of cancer diagnosis are risk factors for anthracycline induced asymptomatic cardiac dysfunction Hypertension Prior cardiomyopathy, Including Familial Anthracycline dose prior to pregnancy Time from Cancer treatment to 1 st Pregnancy
8 Case #1 Patient with history of ALL diagnosed in 1998 at age 17 Treatment with total cumulative anthracycline dose of 233.3mg/m2 Other PMH: neurofibromatosis type 1, osteoporosis, avascular necrosis of bilateral hips, cerebral palsy Pregnancy in 2002 (age 21), delivered prematurely by C-section, child with autism
9 Case #1 Routine echo ordered March 2004, EF was 40-45% Patient had mild SOB and fatigue, NYHA class 2 She was also 10 weeks pregnant
10 Case #1 Started Carvedilol 6.25mg po bid Symptoms resolved and systolic function normalized during the pregnancy Echo in July 2004, in 2 nd trimester, EF 55-60%
11 Case #1 After 2nd trimester, presents with complaints of palpitations occurring once per week. Holter shows, NSR, Repeat Echo shows LVEF unchanged (normal LA Size/Vol index) What are next steps? Increased Coreg to 12.5mg BID & add ASA 81mg Continue with same therapy EP Study Implantable Loop recorder
12 Indications for Reveal Monitor Diagnosis: Syncope Diagnosis of Atrial Fibrillation/Atrial Flutter Management of Arrhythmia Palpitations Cryptogenic Stroke
13 Implantation of Loop Recorder-Cellular Based
14 Reveal XT Patient Assistant Physician Programmable Query Notifications Eight different physician programmable query notifications via the Patient Assistant Programmer interrogation resets all Query notifications Medtronic CareLink System interrogation resets only the Arrhythmia Query notifications
15 Case #1 Monitor revealed short runs of Atrial flutter with RVR, (Aflutter burden 16% Symptomatic/asymptomatic Increased Cardvedilol to 12.5mg BID Follow up one month later she is asymptomatic Aflutter Burden documented to be < 1% per day
16 Case Study #2 31 Y/O Female S/P Allogeneic SCT 11/10. Uncomplicated delivery at 36 weeks (6/2013). Presents with 2 weeks Atypical Chest pain, NYHA Class III symptoms and fevers. H/O GVH disease Electively Intubated 48 Hours after admission BNP=1439 and peak troponin=9.3. Plts=12,000 Pre=SCT LVEF=60%, EKG-Diffuse ST Elevation
17 Abnormal Strain and LVEF with RV Collapse GLPS=-13.1%
18 Case Study #2 Prior to Initiation of therapy, She has several beat runs of NSVT. What is the etiology of his LVSD? Are Viral Titers in this patient population important? Pericarditis/Myocarditis? Once Euvolemic, Carvedilol/Valsartan/IVIG/Steroids/Other? MDACC is to consider Non-invasive vs Invasive approach CMR in high volume centers would be highly considered for diagnosis Invasive approach EMBx in experienced center is also reasonable
19 Etiologic Agents of Myocarditis Viral (Most Common) Adenovirus Coxsackie B, enterovirus ****Cytomegalovirus Parovirus B19 Hepatitis C virus HIV Herpesvirus Epstein-Barr virus *H1N1 Bacterial Myobacterial species Chlamydia pneumoniae Streptococcal species Myoplasma pneumoniae Treponema pallidum Fungal Aspergillus Candida Coccidioides Cryptococcus Histoplasma Protozoal Trypanosoma cruzi Parasitic Schistosomiasis Larva migrans Hypersensitivity Clozapine Sulfonamides Cephalosporins Penicillins Tricyclic antidepressants Autoimmune Activation Smallpox vaccine Giant cell myocarditis Churg-Strauss syndrome Sjogren syndrome Celiac disease Sarcoidosis SLE Takayasu arteritis Wegener granulomatosis
20 EMBx=Myocarditis Normal LHC Pericardiocentesis- No Malignant cells, Mixed Acute/Chronic Inflammatory cells MultiFocal inflammatory Infiltrate. MP,Neut,Eos
21 Improvement of GLPS and LVEF Treated with IVIG for Myocarditis/GVH? GLPS=-18.4%
22 CMR for Diagnosis of Myocarditis MRI Findings in Patients with Myocarditis Cardiac magnetic resonance imaging (MRI) images of a young patient presenting with acute chest pain syndrome due to acute myocarditis. (A) Long-axis and (B) short axis T2-weighted edema images demonstrating focal myocardial edema in the subepicardium of the left midventricular lateral wall (red arrows). Corresponding (C) long-axis and (D) short-axid T1-weighted late gadolinium enhanced images demonstrate presence of typical gadolinium enchancement in the sbuepicardium of the left midventricular lateral wall and the basal septum (red arrows). Kinderman et al., J Am Coll Cardiol 59(9):
23 Case #3 Patient diagnosed with non-hodgkins lymphoma in 1981 at age 16 Adriamycin 480 mg/m2 Amenorrhea after treatment On OCPs until 1998 Stopped OCPs as she thought she was infertile Pregnancy 3 months later at age 33 Reported normal EF prior to pregnancy
24 Case #3 CHF and toxemia at 22 weeks C-section at 26 weeks, daughter with cerebral palsy Treated with Coreg and Captopril with EF of 50% in 2004 In 2013 in setting of H1N1 influenza, EF decreased to 35% At last f/u in 2015, EF 33% with restrictive LV filling pattern, remains on Carvedilol and Captopril
25 Current Guidelines Dutch Echo in 3 rd trimester International Echo before pregnancy or in 1 st trimester Recommendations have not been formulated for ongoing surveillance in pregnant survivors who have normal EF before or in 1 st trimester Sieswerda E, Ann Oncol 2012 Armenian SH, Lancet Oncol 2015
26 Studies EJ of Cancer-vanDalen 2006 Retrospective 53 women Mean anthracycline dose 267mg/m2 2 with CHF following anthracyclines CHF definition = signs/sx No echocardiograms No CHF Low Incidence of CHF American J of OB & Gyn Bar 2003 Prospective 37 women All with anthracycline dose <500mg/m2, mean 400mg/m2 29 with FS > 30%, none with CHF with pregnancy 8 with FS < 30%, 2 of 8 with CHF at delivery, 1 recovered and 1 did not Low Incidence and recovery
27 Recent Study Retrospective 847 patients, 1554 pregnancies Median anthracycline dose 200mg/m2 CMP = EF < 50%, FS < 28%, tx for CMP 43 with CMP 3 with pregnancy (0.3%) 26 prior to pregnancy 8 deteriorated 3 of 8 had normalized before pregnancy 5 after pregnancy Hines MR, J Cancer Surviv 2015.
28 Comparison Incidence of PPCM is 1 in in US, i.e. about 0.03% Incidence of pregnancy assoc. CMP in CCS was 0.3% in Hines study Patients were identified from self reported cardiac events Our experience at MDA higher, 12% incidence of CMP assoc. with pregnancy in CCS More frequent screening of LV function? Sliwa K, European Journal of Heart Failure, 2010.
29 Conclusions Differential Diagnosis should be considered in young women with PPCM Non-invasive approach is ideal, CMR and invasive approaches should be considered at High Volume Centers Recovery of LV function is common with anthracycline provided diagnosis is made early and treatment is started immediately. Management of Modifiable Comorbid conditions may have an important role in successful outcomes
30 Thank you! Twitter- Jean-Bernard
Myocarditis and Pericarditis
Myocarditis and Pericarditis Elias V. Haddad, M.D., FACC Advances in Cardiovascular Care 2012 Kingston, Jamaica December 7, 2012 Financial Disclosures No disclosures relevant to this presentation Learning
More informationPractice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy
Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
More informationCan point of care cardiac biomarker testing guide cardiac safety during oncology trials?
Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University
More informationHow to Evaluate the Heart of Elderly Patients
How to Evaluate the Heart of Elderly Patients Special considerations regarding cardiotoxicity Michael S. Ewer MD The University of Texas M. D. Anderson Cancer Center Why Discuss Cardiac Disease and Cancer
More informationCase Study in Cancer and Cardiotoxicity
Case Study in Cancer and Cardiotoxicity JEAN-BERNARD DURAND, M.D., FCCP, FACC ASSOCIATE PROFESSOR OF MEDICINE MEDICAL DIRECTOR CARDIOMYOPATHY SERVICES UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON,
More informationWhen An MI Is Not An MI. Morning Report July 30, 2003 Ryan Mattison, MD
When An MI Is Not An MI Morning Report July 30, 2003 Ryan Mattison, MD Confounding Factors In This Patient WPW Abnormality Dynamic EKG Changes With Symptoms Myocarditis: Definition As the name implies,
More informationRisk of Subsequent Pregnancy in Women with a History of Peripartum Cardiomyopathy Uri Elkayam, MD
Risk of Subsequent Pregnancy in Women with a History of Peripartum Cardiomyopathy Uri Elkayam, MD Professor of Medicine / Cardiology Professor of Obstetrics and Gynecology University of Southern California
More informationPregnancy in Non-Peripartum Cardiomyopathy
Pregnancy in Non-Peripartum Cardiomyopathy Avraham Shotan, Lubov Vasilenco, Michael Shochat, Mark Kazatsker, David Blondheim, Yaniv Levi, Simcha Meisel, Alicia Vazan Heart Institute, Hillel Yaffe Medical
More informationInteresting EP Cases Catheter ablation to treat congestive heart failure (CHF)
Interesting EP Cases Catheter ablation to treat congestive heart failure (CHF) Yiming WU, MD, PhD. Alaska heart and vascular institute. ywu@alaskaheart.com 907-561-3211 19 yo man transferred for out side
More informationCardio-Oncology at MHI. Kasia Hryniewicz, M.D.
Minneapolis Heart Institute at Abbott Northwestern Hospital Cardio-Oncology at MHI Cardiovascular Nursing Conference Kasia Hryniewicz, M.D. October 7 th, 2015 No disclosure 1 Why cardio-oncology? Background
More information4/11/2017. Cardiomyopathy. John Steuter, MD Bryan Heart. Disclosures. No Conflicts. Cardiomyopathy. WHO Classification
Cardiomyopathy John Steuter, MD Bryan Heart Disclosures No Conflicts Cardiomyopathy WHO Classification Anatomy & physiology of the LV 1. Dilated Enlarged Systolic dysfunction 2. Hypertrophic Thickened
More informationSusan P. D Anna MSN, APRN BC February 14, 2019
Is there Equal Opportunity in Heart Failure?? Susan P. D Anna MSN, APRN BC February 14, 2019 Disclosures: I have no financial disclosures. I am not an expert on this topic, but see a lot of women with
More informationCardiotoxicity: The View of the Cardiologist
Cardiotoxicity: The View of the Cardiologist Dr. Yael Peled, Cardio-Oncology Interactions: 1.Cardiotoxicity following chemotherapy 2. Co existence of cancer and CVD Aging & common risk factors cardiac
More informationXVth Balkan Congress of Radiology Danubius Hotel Helia, October 2017, Budapest, Hungary
XVth Balkan Congress of Radiology Danubius Hotel Helia, 12-14 October 2017, Budapest, Hungary Ružica Maksimović MRI in Myocarditis Faculty of Medicine, University of Belgrade, Centre for Radiology and
More informationCardiomyopathy. Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement
Cardiomyopathy Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement Nebraska Home Office Life Underwriters Association March 20, 2018 1 Cardiomyopathy A myocardial disorder in which
More informationChemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY
Chemotherapy- Associated Heart Failure M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY In last 20 years life-expectancy for patients with cancer
More informationDisclosures. Objectives. SK continued. Two of my patients. First and foremost, why is this important??? 10/26/2016
Disclosures Bayer Pharmaceuticals: clinical trial investigator KellyAnn Light-McGroary, MD, FACC Clinical Assistant Professor Cardiomyopathy Treatment Program University of Iowa Hospitals and Clinics Chief
More informationCancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors
Cardiotoxicity of Cancer Therapies: Pathogenesis, Diagnosis, and Management Edward T.H. Yeh, M.D. Cancer survivors Now nearly 12 million cancer survivors in U.S. according to NCI 15% were diagnosed 2+
More informationPVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.
PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?
More informationTHE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS
88 th ASMA ANNUAL SCIENTIFIC MEETING DENVER - CO April 30- May 4, 2017 THE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS S. BISCONTE (1), J. MONIN (2), N. HUIBAN (3), G. GUIU (2), S. NGUYEN (1), O.
More informationCardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC
Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC Onassis Cardiac Surgery Center Athens Greece Nothing to disclose Financial disclosure Cardiac
More informationPeripartum cardiomyopathy: review and practice guidelines. Hanan ALBackr Associate Professor King Saud university, King Fahad Cardaic center -Riyadh
Peripartum cardiomyopathy: review and practice guidelines Hanan ALBackr Associate Professor King Saud university, King Fahad Cardaic center -Riyadh Outlines Definition of PPCM Dignostic Critaria for peripartum
More informationManaging Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology
Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More information03/14/2019. Scope of the Problem. Objectives
Cardiac Consideration During and After Breast Cancer Treatment Indu G. Poornima M.D Division of Cardiology Scope of the Problem 1 in 8 women will develop breast cancer 3.3 million women are survivors CVD
More informationPericardial disease. Se-Jung Yoon Cardiology division NHIS Ilsan hospital
Pericardial disease Se-Jung Yoon Cardiology division NHIS Ilsan hospital Normal pericardial effusion Normal pericardium Normal pericardium Pericardial Layers: Visceral layer Parietal layer Fibrous pericardium
More informationWhat s New in Cardiac MRI
What s New in Cardiac MRI Katie M. Hawthorne, MD Director, Cardiac MRI Main Line Health Philadelphia Cardiovascular Summit November 18, 2017 Cardiac MRI: Disclosure 2 Disclosures No financial disclosures
More informationHFPEF Echo with Strain vs. MRI T1 Mapping
HFPEF Echo with Strain vs. MRI T1 Mapping Erik Schelbert, MD MS Director, Cardiovascular Magnetic Resonance Assistant Professor of Medicine Heart & Vascular Institute University of Pittsburgh Disclosures
More informationCase 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?
Case 1 A primary care colleague inquires what to do with a patient (HFrEF in NSR) who has a digoxin level of 2.8ng/ml. Level was obtained at 10am, patient takes all medications at one time upon arising
More informationFollowing viral myocarditis, which athlete can re-enter his active sports career?
Following viral myocarditis, which athlete can re-enter his active sports career? ESC Congress 2011 Paris F. Carré University Rennes 1-Pontchaillou Hospital Inserm U642, Rennes - F-35000 The author declares
More informationA Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)
A Light in the Dark: Cardiac MRI and Risk Mitigation J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) Dr. Mikolich has NO financial disclosures relative to
More informationImaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD
Imaging in Heart Failure: A Multimodality Approach Thomas Ryan, MD Heart Failure HFrEF HFpEF EF50% Lifetime risk 20% Prevalence 6M Americans Societal costs - $30B 50% 5-year survival 1 Systolic
More informationMyocarditis Bugs, Drugs, and the Role of Mechanical Circulatory Support
Myocarditis Bugs, Drugs, and the Role of Mechanical Circulatory Support Matthew J. Bock, M.D. Assistant Professor, Division of Pediatric Cardiology Pediatric Heart Failure & Transplantation Loma Linda
More informationSPORT AND ARRHYTHMIA Sports and Physical Exercise in Special Clinical Settings Chairmen: P. Delise, F. Giada. Myocarditis
SPORT AND ARRHYTHMIA Sports and Physical Exercise in Special Clinical Settings Chairmen: P. Delise, F. Giada Myocarditis Brian Olshansky MD Professor Emeritus, University of Iowa Electrophysiologist, Mason
More informationAnthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients
Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients Scottish Cancer Trials Breast Group Meeting Thursday 2 nd February 2017 Dr Peter Henriksen Edinburgh Heart Centre
More informationICD Guidelines: who benefits from an ICD?
ICD Guidelines: who benefits from an ICD? Matthew Bennett Cardiac Electrophysiologist Vancouver Coastal Health, Device Lead Associate Professor, UBC Matthew.bennett@vch.ca Disclosures I have research collaborations
More informationCardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient
Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient Vijay U. Rao, MD, PhD, FACC, FASE Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart
More informationManagement of Heart Failure and Cardiomyopathies in Pregnancy
Management of Heart Failure and Cardiomyopathies in Pregnancy Professor Sanjay Sharma Disclosures: None Epidemiology of Cardiac Disease In Pregnancy Cardiovascular disease in pregnancy is increasing in
More informationReport Documentation Page
Clinical and Pathologic Characteristics of Myocarditis as a Cause of Sudden Death Lena Avedissian, Jennifer A. McNear, David A. Appel, Laudino M. Castillo Rojas, J. Edwin Atwood, Lisa A. Pearse, Robert
More informationCardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics
Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Richard Sheppard MD FRCPC Director of Heart Failure Research Heart Function Clinic Jewish General hospital Objectives 1. Discuss
More informationCardio-oncology: Applying new echo technology to guide therapy
Cardio-oncology: Applying new echo technology to guide therapy Dinesh Thavendiranathan MD, SM, FRCPC, FASE Director, Ted Rogers Program in Cardiotoxicity Prevention Assistant Professor of Medicine Division
More informationMultiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity
Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity Cory V. Noel, M.D. Medical Director of CMR Pediatric Cardiology Outline What is meant by the term cardiotoxicity? Scope of
More informationA Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)
A Light in the Dark: Cardiac MRI and Risk Mitigation J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) Dr. Mikolich has NO financial disclosures relative to
More informationMyocarditis. By : Nader Alaridah MD,PhD
Myocarditis By : Nader Alaridah MD,PhD Background Myocarditis is an inflammatory disease of the cardiac muscle. Histologically, It is described as an inflammatory infiltrate of the myocardium with necrosis
More informationTakotsubo syndrome. Ευτυχία Σμπαρούνη, FACC, FESC
Takotsubo syndrome Ευτυχία Σμπαρούνη, FACC, FESC Definition Takotsubo Apical ballooning Broken heart syndrome Stress cardiomyopathy Cathecholaminergic cardiomyopathy Epidemiology 1990 first report by Japanese
More informationSevere Myocarditis: A 2012 update
Severe Myocarditis: A 2012 update Alain Combes Service de Réanimation ican, Institute of Cardiometabolism and Nutrition Hôpital Pitié-Salpêtrière, AP-HP, Paris Université Pierre et Marie Curie, Paris 6
More information27-year-old professionnal rugby player: asymptomatic
27-year-old professionnal rugby player: asymptomatic Benefits and limits of cardiac MRI in the young athlete with a suspected heart disease. Philippe PAULE Service de Cardiologie, HIA Clermont Tonnerre,
More informationCase based learning: CMR in Heart Failure
Case based learning: CMR in Heart Failure Milind Y Desai, MD FACC FAHA FESC Associate Professor of Medicine Heart and Vascular Institute, Cleveland Clinic Cleveland, OH Disclosures: none Use of Gadolinium
More informationIs it HF secondary to rheumatic heart disease???
Is it HF secondary to rheumatic heart disease??? Is mitral regurg. Is complication of CHF??? Cardiomyopathy Definition The term cardiomyopathy is purely descriptive, meaning disease of the heart muscle
More informationCardiac Toxicities Associated with Cancer Treatment
Cardiac Toxicities Associated with Cancer Treatment Hot Topics in Oncology Care 2017 Silicon Valley Oncology Nursing Society Christine Miaskowski, RN, PhD, FAAN American Cancer Society Clinical Research
More informationQCVC Committees Scientific Activities Central Hall General Information FAC. SPECT tomography has the advantage of quantifying biventricular volumes.
QCVC Committees Scientific Activities Central Hall General Information FAC Thematic Units Arrhythmias and Electrophysiology Basic Research Bioengineering and Medical Informatics Cardiac Surgical Intensive
More informationNew Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care
New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care Sandra M Swain, MD, FACP, FASCO Professor of Medicine Associate Dean for Research Development Georgetown
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationCardiovascular outcomes in survivors of childhood cancer
Cardiovascular outcomes in survivors of childhood cancer Paul Nathan MD, MSc Director, AfterCare Program Division of Haematology/Oncology The Hospital for Sick Children, Toronto Conflicts Nothing to declare
More informationThe Heart Is A Muscle Too! The Cardiomyopathy In Duchenne Muscular Dystrophy
The Heart Is A Muscle Too! The Cardiomyopathy In Duchenne Muscular Dystrophy Linda Cripe MD Professor of Pediatrics Nationwide Children s Hospital/The Ohio State University.... Why are cardiologists
More informationCardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer
Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Dr. Chris Fryer, Pediatric Oncologist, BC Children s Hospital Dr. Sean Virani, Founding Director, UBC Cardiovascular Oncology
More informationMR imaging in suspected acute myocarditis
MR imaging in suspected acute myocarditis Poster No.: C-1954 Congress: ECR 2012 Type: Educational Exhibit Authors: C. Lacroix, D. Bélanger, P. Martin, P. Farand, F. Belzile, G. Gahide; Sherbrooke, QC/CA
More informationClinical aspects of Arrhythmogenic Cardiomyopathies
Clinical aspects of Arrhythmogenic Cardiomyopathies INTERNATIONAL CLINICAL CARDIOVASCULAR GENETICS CONFERENCE 25 May 2018 Dr Hari Raju MBChB PhD ECES FRACP Clinical Associate Professor, Macquarie University,
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationWe report here the case of a 30-year-old professional
Images in Cardiovascular Medicine Cardiac Contusion in a Professional Soccer Player Visualization of Acute and Late Pathological Changes in the Myocardium With Magnetic Resonance Imaging Hajnalka Vago,
More informationStress Echocardiography: Illustrative Cases Sunil Mankad, MD, FACC, FCCP, FASE Associate Professor of Medicine Mayo Clinic College of Medicine Director, Transesophageal Echocardiography Associate Director,
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationHeart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing
EXAMING HEART FAILURE: HOW TO RECOGNIZE AND TREAT THE WEAK HEART What is Heart Failure? Treatment of Heart Failure End Stage Heart Failure Munir S. Janmohamed M.D. FACC Assistant Clinical Professor of
More informationAdvanced Echocardiography in the Evaluation of Chemotherapy Patients
Advanced Echocardiography in the Evaluation of Chemotherapy Patients Juan Carlos Plana, MD, FACC, FASE Co-Director, Cardio-Oncology Center Section of Cardiovascular Imaging Department of Cardiovascular
More informationPediatric influenza-associated deaths in Arizona,
Pediatric influenza-associated deaths in Arizona, 2004-2012 (Poster is shared here as an 8.5 x11 document for easier viewing. All content is identical, though graphs and tables are formatted differently.)
More informationLate Effects in Pediatric Cancer Survivors
Late Effects in Pediatric Cancer Survivors LISA K OPP, DO ASSOCIATE PROFESSOR THE UNIVERSITY OF ARIZONA DEPARTMENT OF PEDIATRICS DIVISION OF HEMATOLOGY/ONCOLOGY/BMT Objectives Review Childhood Cancer and
More informationRestrictive Cardiomyopathy
ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures
More informationEchocardiographic Cardiovascular Risk Stratification: Beyond Ejection Fraction
Echocardiographic Cardiovascular Risk Stratification: Beyond Ejection Fraction October 4, 2014 James S. Lee, M.D., F.A.C.C. Associates in Cardiology, P.A. Silver Spring, M.D. Disclosures Financial none
More informationConsiderations on Phasing Out Medications In the Treatment of Peripartum Cardiomyopathy After Full Recovery James D. Fett, MD
Considerations on Phasing Out Medications In the Treatment of Peripartum Cardiomyopathy After Full Recovery James D. Fett, MD Co-Director, Peripartum Cardiomyopathy Network, Coordinating Center, University
More informationDiagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta
Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations
More informationDISCLOSURE. Echocardiography in Systemic Diseases: Questions. Relevant Financial Relationship(s) None. Off Label Usage None 5/7/2018
Echocardiography in Systemic Diseases: Questions Sunil Mankad, MD, FACC, FCCP, FASE Associate Professor of Medicine Mayo Clinic College of Medicine Director, Transesophageal Echocardiography Associate
More informationPeripartum Cardiomyopathy. Lavanya Rai Manipal
Peripartum Cardiomyopathy Lavanya Rai Manipal Definition - PPCM - Dilated cardiomyopathy of unknown cause resulting in cardiac failure that occurs in the peripartum period in women without any preexisting
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationManaging LV Impairment with Cancer Therapies
British Society for Heart Failure Revalidation & Training Day London, March 2017 Managing LV Impairment with Cancer Therapies Zaheer Yousef BSc MBBS MD FESC FRCP Heart Muscle Diseases & Heart Function
More informationVasculitides in Surgical Neuropathology Practice
Vasculitides in Surgical Neuropathology Practice USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationContemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More informationWhat s new in Hypertrophic Cardiomyopathy?
What s new in Hypertrophic Cardiomyopathy? Dr Andris Ellims HCM Clinic @ The Alfred Hypertrophic Cardiomyopathy = otherwise unexplained LV hypertrophy* 1 in 500 prevalence most common inherited cardiovascular
More informationValve Disease in the Pregnant Patient
Valve Disease in the Pregnant Patient Julie B. Damp, MD December 6, 2012 VanderbiltHeart.com If single, do not allow marriage. If fertile, do not allow pregnancy. If pregnant, do not allow delivery. If
More informationΕμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες
Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou
More informationLeft ventricular non-compaction: the New Cardiomyopathy on the Block
Left ventricular non-compaction: the New Cardiomyopathy on the Block Aamir Jeewa MB BCh, FAAP, FRCPC Section Head, Cardiomyopathy & Heart Function Program The Hospital for Sick Children Assistant Professor
More informationMyocarditis is clinically and pathologically defined as
Contemporary Reviews in Cardiovascular Medicine Myocarditis Current Trends in Diagnosis and Treatment Jared W. Magnani, MD; G. William Dec, MD Myocarditis is clinically and pathologically defined as inflammation
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationΜυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα
Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Estimated and projected cancer survivors in USA de Moor JS et al. Cancer Epidemiol Biomarkers Prev 2013 Causes of
More informationCASE STUDIES IN ADVANCED HEART FAILURE
CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING
More informationMyocardites aigües MYOCARDITIS. 71 ème Journée Française de Médecine. Jean-Noël Trochu Institut du Thorax CHU de Nantes
Plain definition: MYOCARDITIS inflammation of the myocardium Myocardites aigües 71 ème Journée Française de Médecine Jean-Noël Trochu Institut du Thorax CHU de Nantes But numerous classification schemes:
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationCardiac Sarcoidosis. Millee Singh DO Non Invasive Cardiology First Coast Heart and Vascluar
Cardiac Sarcoidosis Millee Singh DO Non Invasive Cardiology First Coast Heart and Vascluar Introduction Multisystem granulomatous disease of unknown etiology characterized by noncaseating granulomas in
More informationBreast Cancer and the Heart
Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationNewly Diagnosed Heart Failure patient: When to Order an MRI and Why
Newly Diagnosed Heart Failure patient: When to Order an MRI and Why Jennifer Dickerson MD Assistant Professor of Clinical Internal Medicine Director, The Ohio State University Echocardiography Laboratory
More informationMyocarditis. Dr. Lewis Au Clinical Research Fellow (melanoma) Royal Marsden Hospital
Myocarditis Dr. Lewis Au Clinical Research Fellow (melanoma) Royal Marsden Hospital Mrs JR (1) 78yo lady Depression on citalopram Otherwise no other active health problems, ECOG 0 Sept 2015: 25mm neurotropic
More informationPregnancy and Heart Disease. Alexandra A Frogoudaki Adult Congenital Heart Clinic ATTIKON University Hospital
Pregnancy and Heart Disease Alexandra A Frogoudaki Adult Congenital Heart Clinic ATTIKON University Hospital Pregnancy is not a state Hemodynamic changes During pregnancy Estrogens 1. Renin 2.
More informationStrain Imaging: Myocardial Mechanics Simplified and Applied
9/28/217 Strain Imaging: Myocardial Mechanics Simplified and Applied John Gorcsan III, MD Professor of Medicine Director of Clinical Research Division of Cardiology VECTORS OF CONTRACTION Shortening Thickening
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationWhen to ablate patients with premature ventricular complexes?
When to ablate patients with premature ventricular complexes? Nikolaos Fragakis Assistant Professor, FESC 3rd University Cardiology Department Hippokration Hospital, Thessaloniki 58 year-old female Case
More informationDobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure
Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure Yuksel Cavusoglu, KU Mert, A Nadir, F Mutlu, E Gencer, T Ulus, A Birdane
More informationAtlas of the Vasculitic Syndromes
CHAPTER e40 Atlas of the Vasculitic Syndromes Carol A. Langford Anthony S. Fauci Diagnosis of the vasculitic syndromes is usually based upon characteristic histologic or arteriographic findings in a patient
More informationAcute cardiogenic shock with standing-still heart
Acute cardiogenic shock with standing-still heart Ga Yeon Lee April, 21, 2017 Division of cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, South Korea
More information